ERBB2 and breast cancer: A retrospective analysis of 774 biopsy samples from the TransATAC study, performed on post-menopausal women with ER+, HER2− breast cancer and treated for 5 years with tamoxifen or anastrazole, compared 6 tests: the Oncotype DX test, Prosigna, EndoPredict, Breast Cancer Index (BCI), Clinical Treatment Score and immunohistochemistry with 4-markers.